Sulfide and methemoglobinemia

Hydrogen sulfide intoxication induced brain injury and methylene blue

Hydrogen sulfide (H₂S) remains a chemical hazard in the gas and farming industry. It is easy to manufacture from common chemicals and thus represents a potential threat for the civilian population. It is also employed as a method of suicide, for which incidence has recently increased in the US. H₂S is a mitochondrial poison and exerts its toxicity through mechanisms that are thought to result from its high affinity to various metallo-proteins (such as - but not exclusively- the mitochondrial cytochrome c oxidase) and interactions with cysteine residues of proteins. Ion channels with critical implications for the cardiac and the brain functions appear to be affected very early during and following H₂S exposure, an effect which is rapidly reversible during a light intoxication. However, during severe H₂S intoxication, a coma, associated with a reduction in cardiac contractility, develops within minutes or even seconds leading to death by complete electro-mechanical dissociation of the heart. If the level of intoxication is milder, a rapid and spontaneous recovery of the coma occurs as soon as the exposure stops. The risk, although probably very small, of developing long-term debilitating motor or cognitive deficits is present. One of the major challenges impeding our effort to offer an effective treatment against H₂S intoxication after exposure is that the pool of free/soluble H₂S almost immediately disappears from the body preventing agents trapping free H₂S (cobalt or ferric compounds) to play their protective role. This paper (1) presents and discusses the neurological symptoms and lesions observed in various animals models and in humans following an acute exposure to sub-lethal or lethal levels of H₂S, (2) reviews the potential interest of methylene blue (MB), a potent cyclic redox dye - currently used for the treatment of methemoglobinemia - which has potential rescuing effects on the mitochondrial activity, as an antidote against sulfide intoxication.

Methylene Blue Administration During and After Life-Threatening Intoxication by Hydrogen Sulfide: Efficacy Studies in Adult Sheep and Mechanisms of Action

Exposure to toxic levels of hydrogen sulfide (H2S) produces an acute cardiac depression that can be rapidly fatal. We sought to characterize the time course of the cardiac effects produced by the toxicity of H2S in sheep, a human sized mammal, and to describe the in vivo and in vitro antidotal properties of methylene blue (MB), which has shown efficacy in sulfide intoxicated rats. Infusing NaHS (720 mg) in anesthetized adult sheep produced a rapid dilation of the left ventricular with a decrease in contractility, which was lethal within about 10 min by pulseless electrical activity. MB (7 mg/kg), administered during sulfide exposure, maintained cardiac contractility and allowed all of the treated animals to recover. At a dose of 350 mg NaHS, we were able to produce an intoxication, which led to a persistent decrease in ventricular function for at least 1 h in nontreated animals. Administration of MB, 3 or 30 min after the end of exposure, whereas all free H2S had already vanished, restored cardiac contractility and the pyruvate/lactate (P/L) ratio. We found that MB exerts its antidotal effects through at least 4 different mechanisms: (1) a direct oxidation of free sulfide; (2) an increase in the pool of "trapped" H2S in red cells; (3) a restoration of the mitochondrial substrate-level phosphorylation; and (4) a rescue of the mitochondrial electron chain. In conclusion, H2S intoxication produces acute and long persisting alteration in cardiac function in large mammals even after all free H2S has vanished. MB exerts its antidotal effects against life-threatening sulfide intoxication via multifarious properties, some of them unrelated to any direct interaction with free H2S.

Is exogenous hydrogen sulfide a relevant tool to address physiological questions on hydrogen sulfide?

This review challenges the use of solutions of dissolved exogenous H2S in the literature as a tool to determine the potential physiological functions of endogenous H2S as well as its putative therapeutic applications. Our major point of contention is that solutions of dissolved H2S are used in vitro at concentrations, within the high microM range, which are above the concentrations of dissolved H2S found in blood and tissues during lethal H2S exposure in vivo. In addition, since the levels of toxicity are extremely variable among cell types, a property that is seldom acknowledged, the physiological relevance of data obtained after local or in-vitro administrations of H2S at concentrations of few microM is far from certain. Conversely, the rate of disappearance of the dissolved pool of H2S in the body (being trapped or oxidized), which we found to be at least of several micromoles/kg/min, is so rapid in vivo that if relatively low quantities of H2S, i.e. few micromoles for instance, are administered, no change in H2S concentrations in the body is to be expected, unless toxic levels are used. Protocols looking at the effects of compounds slowly releasing H2S must also resolve a similar conundrum, as their effects must be reconciled with the unique ability of the blood and tissues to get rid of H2S and the steepness of the dose-toxic effects relationship. Only by developing a comprehensive framework in which H2S metabolism and toxicity will be used as a rationale to justify any experimental approach will we be able to bring definitive evidence supporting a protective role for exogenous H2S, if any, and its putative function as an endogenous mediator.

Oxygen deficit and H2S in hemorrhagic shock in rats

Introduction

Hemorrhagic shock induced O₂ deficit triggers inflammation and multiple organ failure (MOF). Endogenous H₂S has been proposed to be involved in MOF since plasma H₂S concentration appears to increase in various types of shocks and to predict mortality. We tested the hypothesis that H₂S increases during hemorrhagic shock associated with O₂ deficit, and that enhancing H₂S oxidation by hydroxocobalamin could reduce inflammation, O₂ deficit or mortality.

Methods

We used a urethane anesthetized rat model, where 25 ml/kg of blood was withdrawn over 30 minutes. O₂ deficit, lactic acid, tumor necrosis factor (TNF)-alpha and H₂S plasma concentrations (Siegel method) were measured before and after the bleeding protocol in control animals and animals that received 140 mg/kg of hydroxocobalamin. The ability to oxidize exogenous H₂S of the plasma and supernatants of the kidney and heart homogenates was determined in vitro.

Results

We found that withdrawing 25 ml/kg of blood led to an average oxygen deficit of 122 ± 23 ml/kg. This O₂ deficit was correlated with an increase in the blood lactic acid concentration and mortality. However, the low level of absorbance of the plasma at 670 nm (A₆₇₀), after adding N, N-Dimethyl-p-phenylenediamine, that is, the method used for H₂S determination in previous studies, did not reflect the presence of H₂S, but was a marker of plasma turbidity. There was no difference in plasmatic A₆₇₀ before and after the bleeding protocol, despite the large oxygen deficit. The plasma sampled at the end of bleeding maintained a very large ability to oxidize exogenous H₂S (high μM), as did the homogenates of hearts and kidneys harvested just after death. Hydroxocobalamin concentrations increased in the blood in the μM range in the vitamin B12 group, and enhanced the ability of plasma and kidneys to oxidize H₂S. Yet, the survival rate, O₂ deficit, H₂S plasma concentration, blood lactic acid and TNF-alpha levels were not different from the control group.

Conclusions

In the presence of a large O₂ deficit, H₂S did not increase in the blood in a rat model of untreated hemorrhagic shock. Hydroxocobalamin, while effective against H₂S in vitro, did not affect the hemodynamic profile or outcome in our model.

Ventilatory and metabolic effects of exogenous hydrogen sulfide

Acute H(2)S intoxication produces an increase in ventilation followed by a fatal central apnea. The sites of mediation of H(2)S induced hyperpnea and apnea have been investigated since the early 20th century in various animal models. Hyperpnea is mediated by the arterial chemoreceptors, an effect that can be reproduced by injecting a solution of H(2)S at very high concentrations (high millimolar range), while the fatal apnea, which typically occurs above 1000 ppm in humans, appears to result from the cessation of the activity of the medullary respiratory neurons. More recently, moderate levels of exogenous H(2)S (20-80 ppm) have been shown to reduce, within minutes, the metabolic rate, akin to hypoxia-induced hypometabolism. This response appears to be specific to small sized mammals. The pathway through which low levels of inhaled H(2)S could exert such a powerful effect may be very relevant to the physiological mechanisms controlling non-ATP "metabolic" production. Finally, endogenous H(2)S, produced from cysteine, has been proposed to transduce the effects of hypoxia in the carotid bodies. H(2)S remains a mysterious gas: it is labile, difficult/impossible to properly measure in vivo, its oxidation can take place in most tissues including the blood, and it can affect multiple cellular pathways. The demarcation between effects reflecting a putative physiological function and those related to H(2)S poisoning remains however to be established.

Inhibitory effects of hyperoxia and methemoglobinemia on H(2)S induced ventilatory stimulation in the rat

The aim of this study was to clarify, using in vitro and in vivo approaches in the rat, the site of mediation of the inhibition of H(2)S induced arterial chemoreceptor stimulation, by hyperoxia and methemoglobinemia. We first determined the ventilatory dose-response curves during intravenous injections of H(2)S. A very high dose of NaHS, i.e. 0.4 μmol (concentration: 800 μM), was needed to stimulate breathing within 1s following i.v. injection. Above this level (and up to 2.4 μmol, with a concentration of 4800 μM), a dose-dependent effect of H(2)S injection was observed. NaHS injection into the thoracic aorta produced the same effect, suggesting that within one circulatory time, H(2)S pulmonary exchange does not dramatically reduce H(2)S concentrations in the arterial blood. The ventilatory response to H(2)S was abolished in the presence of MetHb (12.8%) and was significantly depressed in hyperoxia and, surprisingly, in 10% hypoxia. MetHb per se did not affect the ventilatory response to hypoxia or hyperoxia, but dramatically enhanced the oxidation of H(2)S in vitro, with very fast kinetics. These findings suggest that, the decrease/oxidation of exogenous H(2)S in the blood is the primary effect of MetHb in vivo. In contrast, the in vitro oxidative properties of blood for H(2)S were not affected by the level of [Formula: see text] between 23 and >760 mmHg. This suggests that the inhibition of the ventilatory response to H(2)S by hyperoxia during aortic or venous injection originates within the CB and not in the blood. The implications of these results on the role of endogenous H(2)S in the arterial chemoreflex are discussed.

Hypoxia-induced arterial chemoreceptor stimulation and hydrogen sulfide: too much or too little?

This brief review presents and discusses some of the important issues surrounding the theory which asserts that endogenous hydrogen sulfide (H(2)S) is the mediator of, or at least an important contributor to, hypoxia-induced arterial chemorereceptor stimulation. The view presented here is that before H(2)S can seriously be considered as a candidate for transducing the O(2)-signal in the carotid bodies (CB), fundamental contradictions need to be resolved. One of these major contradictions is certainly the discrepancy between the levels of H(2)S endogenously present in the CB during hypoxia compared to the levels required to stimulate the arterial chemoreceptors in vitro. Very small amounts of H(2)S are thought to be produced endogenously during a given level of hypoxia, yet the partial pressure of tissue H(2)S which is needed to produce an effect commensurate with that of hypoxia is thousands to millions of times higher. This review discusses this and other contradictions in light of what is known about H(2)S concentration and production in various tissues, the lessons we have learnt from the response to exogenous sulfide and the ability of the blood and the mitochondria to oxidize very large amounts of sulfide. These considerations suggest that the increased production of H(2)S in hypoxia and exogenous sulfide cannot produce the same effect on the carotid bodies and breathing. While the effects of the endogenous H(2)S on breathing remains to be established, the effects exogenous sulfide can be accounted for by its long established toxicity on cytochrome C oxidase.